The Effect of Anemia on Prognostic in Non-Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy
Downloads
Introduction: Lung cancer has the highest incidence and mortality rate, which contributes to approximately 2.2 million cancer cases (11.4%) of total cancers worldwide. More than 70% of lung cancer cases present in the late, non-operable stage. Anemia is one of the conditions that could precipitate cancers and affect the patient's clinical presentation, including tissue oxygenation, organ function, and quality of life. It could also increase the risk of bleeding, post-operative mortality, and iron absorption rate in the case of ineffective erythropoiesis. All of these could affect the prognostic factor of the cancer. This study aimed to evaluate the effect of the severity of anemia on overall survival (OS) and progression-free survival (PFS) in non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Methods: This was a retrospective cohort study involving 80 subjects of NSCLC patients treated with platinum-based chemotherapy from January 2018 to December 2020. Subjects were divided into two groups (39 patients in the normal group and 41 patients in the anemia group).
Results: The mean pre-treatment hemoglobin (Hb) was 10.55 ± 1.25 g/dL in NSCLC patients with anemia. The bone metastasis, OS, and PFS values of the normal and anemia groups were significant (p = 0.008; p = 0.002; p = 0.27). Anemia was significantly related to OS (r = 0.146, p = 0.000) and PFS (r = 0.264, p = 0.000) in NSCLC patients treated with platinum-based chemotherapy.
Conclusion: Higher severity of anemia can reduce OS and PFS in NSCLC patients treated with platinum-based chemotherapy.
(IARC) IA for R on C. Latest Global Cancer Data: Cancer Burden Rises to 19.3 Million New Cases and 10.0 Million Cancer Deaths in 2020. Geneva, https://www.iarc.who.int/faq/latest-global-cancer-data-2020-qa/ (2020).
(KPKN) KPKN. Pedoman Nasional Pelayanan Kedokteran Kanker Paru. Jakarta, 2017.
Listyoko AS, Herman AF, Merdekawati RD. Profil Tumor Paru pada IRNA 1 RS Saiful Anwar Malang Tahun 2015. Makal disajikan dalam Present Profil Tumor.
Harrison LB, Shasha D, White C, et al. Radiotherapy-Associated Anemia: The Scope of the Problem. Oncologist 2000; 5 Suppl 2: 1–7. [PubMed]
Xiong Y, Zhao N, Zheng Y, et al. Prognostic Value of Pretreatment Inflammatory Biomarkers in Advanced Lung Adenocarcinoma Patients Receiving First-Line Pemetrexed/Platinum Doublet. Tumour Biol 2017; 39: 1010428317701639. [PubMed]
Zhang Y-H, Lu Y, Lu H, et al. Development of a Survival Prognostic Model for Non-small Cell Lung Cancer. Front Oncol 2020; 10: 362. [PubMed]
Xu C, Gao Y, Li L, et al. [Impact of Anemia on Chemotherapy Efficacy and Prognosis in Patients with Advanced Non-Small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2010; 13: 968–974. [PubMed]
Xie D, Allen MS, Marks R, et al. Nomogram Prediction of Overall Survival for Patients with Non-Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood Markers. Eur J Cardiothorac Surg 2018; 53: 1214–1222. [PubMed]
Chen C, Song Z, Wang W, et al. Baseline Anemia and Anemia Grade are Independent Prognostic Factors for Stage IV Non-Small Cell Lung Cancer. Mol Clin Oncol 2021; 14: 59. [PubMed]
Kenar G, Köksoy EB, Ürün Y, et al. Prevalence, Etiology and Risk Factors of Anemia in Patients with Newly Diagnosed Cancer. Support Care Cancer 2020; 28: 5235–5242. [PubMed]
Han SV, Park M, Kwon Y-M, et al. Mild Anemia and Risk for All-Cause, Cardiovascular and Cancer Deaths in Apparently Healthy Elderly Koreans. Korean J Fam Med 2019; 40: 151–158. [PubMed]
Supartono S, Suryanto A. Faktor-Faktor yang Mempengaruhi Ketahanan Hidup Satu Tahun Penderita Kanker Paru Stadium Lanjut di RSUP Dr. Kariadi Semarang. Medica Hosp J Clin Med; 1. Epub ahead of print 8 February 2013. [Journal]
Subak M, Aksel N, Öztürk YK. Incıdence of Anemıa in Cases wıth Lung Cancer at the Tıme of Dıagnosıs and Relatıon between Cancer Types. Forbes J Med; 1. Epub ahead of print 1 November 2020. [ResearchGate]
Syahruddin E, Hudoyo A, Jusuf A. Respons dan Toleransi Pasien Adenokarsinoma Paru Stage III dan IV untuk Pemberian Kemoterapi dengan Rejimen Paclitaxel (Paxus®) Plus Carboplatin. J Respirologi Indones 2010; 30: 105–111. [Journal]
Deng Q, Yang H, Zhang X, et al. [Correlation between Pre-Treatment Anemia and Prognosis in Non-Small Cell Lung Cancer Patients]. Zhongguo Fei Ai Za Zhi 2010; 13: 722–726. [PubMed]
Gascón P, Nagarkar R, Å makal M, et al. A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients with Advanced NSCLC. J Thorac Oncol 2020; 15: 190–202. [PubMed]
Gauthier I, Ding K, Winton T, et al. Impact of Hemoglobin Levels on Outcomes of Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer: The JBR.10 Trial Experience. Lung Cancer 2007; 55: 357–363. [PubMed]
Lee S, Eo W, Jeon H, et al. Prognostic Significance of Host-Related Biomarkers for Survival in Patients with Advanced Non-Small Cell Lung Cancer. J Cancer 2017; 8: 2974–2983. [PubMed]
Huang Y, Wei S, Jiang N, et al. The Prognostic Impact of Decreased Pretreatment Haemoglobin Level on the Survival of Patients with Lung Cancer: A Systematic Review and Meta-Analysis. BMC Cancer 2018; 18: 1235. [PubMed]
Aoe K, Hiraki A, Maeda T, et al. Serum Hemoglobin Level Determined at the First Presentation is a Poor Prognostic Indicator in Patients with Lung Cancer. Intern Med 2005; 44: 800–804. [PubMed]
Liu Y, Bai Y-P, Zhou Z-F, et al. Preoperative Anemia as a Prognostic Factor in Patients with Lung Cancer: A Systematic Review and Meta-Analysis of Epidemiological Studies. J Cancer 2019; 10: 2047–2056. [PubMed]
Wan S, Lai Y, Myers RE, et al. Post-Diagnosis Hemoglobin Change Associates with Overall Survival of Multiple Malignancies – Results from a 14-Year Hospital-Based Cohort of Lung, Breast, Colorectal, and Liver Cancers. BMC Cancer 2013; 13: 340. [PubMed]
Copyright (c) 2024 Ulfah Kartikasari, Suryanti Dwi Pratiwi, Tri Wahju Astuti, Nanik Setijowati
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (